Anti-angiogenic therapy: From laboratory to the patient

F. O. Ademuyiwa; G. W. Sledge

doi:10.1017/S1470903109990186

Anti-angiogenic therapy: From laboratory to the patient

Research output: Contribution to journal › Review article › peer-review

Abstract

Angiogenesis, or new vessel formation, plays a key role in the process of tumor growth and metastasis in breast cancer. Recent large phase-III trials (E2100 and AVADO) demonstrate the clinical utility of bevacizumab in combination with front-line taxane-based chemotherapy in patients with metastatic breast cancer, leading to its recent approval in the United States and Europe. Several other anti-angiogenic strategies against vascular endothelial growth factor are in various phases of clinical development. This paper reviews the data on bevacizumab in metastatic breast cancer and other anti-angiogenic strategies on development in breast cancer.

Original language	English
Article number	e4
Journal	Breast Cancer Online
Volume	12
Issue number	2
DOIs	https://doi.org/10.1017/S1470903109990186
State	Published - 2009

Keywords

Bevacizumab
Breast cancer
Tyrosine kinase inhibitor
VEGF

Access to Document

10.1017/S1470903109990186

Cite this

@article{213f8bddeed14d33920fa515c2867979,

title = "Anti-angiogenic therapy: From laboratory to the patient",

abstract = "Angiogenesis, or new vessel formation, plays a key role in the process of tumor growth and metastasis in breast cancer. Recent large phase-III trials (E2100 and AVADO) demonstrate the clinical utility of bevacizumab in combination with front-line taxane-based chemotherapy in patients with metastatic breast cancer, leading to its recent approval in the United States and Europe. Several other anti-angiogenic strategies against vascular endothelial growth factor are in various phases of clinical development. This paper reviews the data on bevacizumab in metastatic breast cancer and other anti-angiogenic strategies on development in breast cancer.",

keywords = "Bevacizumab, Breast cancer, Tyrosine kinase inhibitor, VEGF",

author = "Ademuyiwa, {F. O.} and Sledge, {G. W.}",

year = "2009",

doi = "10.1017/S1470903109990186",

language = "English",

volume = "12",

journal = "Breast Cancer Online",

issn = "1470-9031",

number = "2",

}

TY - JOUR

T1 - Anti-angiogenic therapy

T2 - From laboratory to the patient

AU - Ademuyiwa, F. O.

AU - Sledge, G. W.

PY - 2009

Y1 - 2009

N2 - Angiogenesis, or new vessel formation, plays a key role in the process of tumor growth and metastasis in breast cancer. Recent large phase-III trials (E2100 and AVADO) demonstrate the clinical utility of bevacizumab in combination with front-line taxane-based chemotherapy in patients with metastatic breast cancer, leading to its recent approval in the United States and Europe. Several other anti-angiogenic strategies against vascular endothelial growth factor are in various phases of clinical development. This paper reviews the data on bevacizumab in metastatic breast cancer and other anti-angiogenic strategies on development in breast cancer.

AB - Angiogenesis, or new vessel formation, plays a key role in the process of tumor growth and metastasis in breast cancer. Recent large phase-III trials (E2100 and AVADO) demonstrate the clinical utility of bevacizumab in combination with front-line taxane-based chemotherapy in patients with metastatic breast cancer, leading to its recent approval in the United States and Europe. Several other anti-angiogenic strategies against vascular endothelial growth factor are in various phases of clinical development. This paper reviews the data on bevacizumab in metastatic breast cancer and other anti-angiogenic strategies on development in breast cancer.

KW - Bevacizumab

KW - Breast cancer

KW - Tyrosine kinase inhibitor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=70349185714&partnerID=8YFLogxK

U2 - 10.1017/S1470903109990186

DO - 10.1017/S1470903109990186

M3 - Review article

AN - SCOPUS:70349185714

VL - 12

JO - Breast Cancer Online

JF - Breast Cancer Online

SN - 1470-9031

IS - 2

M1 - e4

ER -

Anti-angiogenic therapy: From laboratory to the patient

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this